Replimune Group (REPL) Stock Price, News & Analysis

Company Overview

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company’s approach uses genetically engineered viruses designed to selectively replicate in tumors, directly destroy cancer cells and stimulate a broader immune response against malignant tissue.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 intended for use in patients with advanced solid tumors. The company has evaluated RP1 as a standalone therapy and in combination with immune checkpoint inhibitors. Its pipeline has also included additional investigational oncolytic immunotherapies, including RP2 and RP3, which are designed with different payloads and mechanisms to enhance antitumor immune activity.

Founded in 2015, Replimune is headquartered in the United States and conducts clinical development through research and collaborations involving patients with advanced cancers in multiple regions. The company’s programs remain focused on advancing novel immunotherapies through clinical testing and potential regulatory approval.

Key Stats

• Today's Range: $12.79 to $13.44
• 50-Day Range: $11.83 to $15.98
• 52-Week Range: $1.50 to $16.33
• Volume: 2.02 million shs
• Average Volume: 2.22 million shs
• Market Capitalization: $1.26 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

Replimune Group Stock Analysis - MarketRank™

Replimune Group scored higher than 25% of companies evaluated by MarketBeat, and ranked 776th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Replimune Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 2 sell ratings.

Downside Risk

Replimune Group has a consensus price target of $12.00, representing about 10.6% downside from its current price of $13.42.

Amount of Analyst Coverage

Replimune Group has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Replimune Group are expected to grow in the coming year, from ($2.82) to ($2.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Replimune Group is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Replimune Group is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Replimune Group has a P/B Ratio of 6.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.06% of the float of Replimune Group has been sold short.

Short Interest Ratio / Days to Cover

Replimune Group has a short interest ratio ("days to cover") of 10.83, which indicates bearish sentiment.

Change versus previous month

Short interest in Replimune Group has recently increased by 1.64%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Replimune Group does not currently pay a dividend.

Dividend Growth

Replimune Group does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.41

News Sentiment

Replimune Group has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Replimune Group this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

MarketBeat Follows

3 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,038,364.00 in company stock.

Percentage Held by Insiders

5.40% of the stock of Replimune Group is held by insiders.

Percentage Held by Institutions

92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:REPL
• CIK: 1737953
• Web: www.replimune.com
• Phone: (781) 222-9600
• Fax: N/A
• Employees: 465
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Replimune Group: $12.00
• High Price Target: $21.00
• Low Price Target: $2.00
• Potential Upside/Downside: -10.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$313.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -159.32%
• Return on Assets: -90.84%

Debt

• Debt-to-Equity Ratio: 1.00
• Current Ratio: 5.23
• Quick Ratio: 5.23

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.01 per share
• Price / Book: 6.68

Miscellaneous

• Outstanding Shares: 93,800,000
• Free Float: 88,733,000
• Market Cap: $1.26 billion
• Optionable: Optionable
• Beta: 0.93